D. Perner

521 total citations
22 papers, 390 citations indexed

About

D. Perner is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, D. Perner has authored 22 papers receiving a total of 390 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Hepatology, 10 papers in Epidemiology and 7 papers in Infectious Diseases. Recurrent topics in D. Perner's work include Hepatitis C virus research (20 papers), Hepatitis B Virus Studies (9 papers) and HIV/AIDS drug development and treatment (7 papers). D. Perner is often cited by papers focused on Hepatitis C virus research (20 papers), Hepatitis B Virus Studies (9 papers) and HIV/AIDS drug development and treatment (7 papers). D. Perner collaborates with scholars based in Germany, United States and Switzerland. D. Perner's co-authors include Christoph Sarrazin, S. Süsser, Stefan Zeuzem, Johannes Vermehren, Julia Dietz, Stefan Zeuzem, Martin Welker, Nicole Forestier, Gavin Cloherty and Kai‐Henrik Peiffer and has published in prestigious journals such as PLoS ONE, Hepatology and Journal of Hepatology.

In The Last Decade

D. Perner

22 papers receiving 389 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
D. Perner Germany 9 355 315 108 39 27 22 390
Zunaira Awan Pakistan 10 277 0.8× 261 0.8× 49 0.5× 39 1.0× 21 0.8× 15 343
J. Albrecht United States 10 391 1.1× 368 1.2× 64 0.6× 33 0.8× 54 2.0× 18 449
K Ohba Japan 4 420 1.2× 397 1.3× 55 0.5× 21 0.5× 33 1.2× 6 474
Atsushi Ozasa Japan 8 274 0.8× 264 0.8× 38 0.4× 62 1.6× 11 0.4× 10 377
Rosanna Fontana Italy 13 588 1.7× 618 2.0× 59 0.5× 32 0.8× 12 0.4× 35 700
Dessislava I. Dimitrova United States 8 688 1.9× 588 1.9× 161 1.5× 67 1.7× 74 2.7× 11 775
Arleta Kowala‐Piaskowska Poland 12 220 0.6× 203 0.6× 52 0.5× 51 1.3× 16 0.6× 56 376
Uta Naumann Germany 12 575 1.6× 578 1.8× 70 0.6× 36 0.9× 17 0.6× 32 680
J. H. Hoofnagle United States 11 275 0.8× 295 0.9× 64 0.6× 54 1.4× 61 2.3× 14 414
Vanessa Haynes–Williams United States 8 448 1.3× 448 1.4× 44 0.4× 54 1.4× 17 0.6× 9 561

Countries citing papers authored by D. Perner

Since Specialization
Citations

This map shows the geographic impact of D. Perner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Perner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Perner more than expected).

Fields of papers citing papers by D. Perner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Perner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Perner. The network helps show where D. Perner may publish in the future.

Co-authorship network of co-authors of D. Perner

This figure shows the co-authorship network connecting the top 25 collaborators of D. Perner. A scholar is included among the top collaborators of D. Perner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Perner. D. Perner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Maasoumy, Benjamin, Johannes Vermehren, Martin‐Walter Welker, et al.. (2016). Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens. Journal of Hepatology. 65(3). 473–482. 53 indexed citations
2.
Penna-Martinez, Marissa, D. Perner, S. Süsser, et al.. (2016). IL28B gene variants and glucose metabolism in Type 2 Diabetes. Human Immunology. 77(12). 1280–1283. 4 indexed citations
3.
Dietz, Julia, Daniel Rupp, S. Süsser, et al.. (2016). Investigation of NS3 Protease Resistance-Associated Variants and Phenotypes for the Prediction of Treatment Response to HCV Triple Therapy. PLoS ONE. 11(6). e0156731–e0156731. 3 indexed citations
4.
Fevery, Bart, S. Süsser, Oliver Lenz, et al.. (2015). Comparison of three quantitative HCV RNA assays in samples from HCV genotype 1- or 4-infected patients treated with the NS3/4A protease inhibitor simeprevir. Journal of Clinical Virology. 72. 133–140. 8 indexed citations
5.
Dietz, Julia, et al.. (2015). Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients. PLoS ONE. 10(8). e0134395–e0134395. 61 indexed citations
6.
Dietz, Julia, Daniel Rupp, D. Perner, et al.. (2015). P0818 : Analysis of NS3 protease resistance-associated variants and phenotypes for the prediction of treatment response to HCV triple therapy. Journal of Hepatology. 62. S643–S643. 1 indexed citations
7.
Dietz, Julia, et al.. (2015). P0900 : Consideration of viral resistance for optimization of direct antiviral therapy of chronic hepatitis C. Journal of Hepatology. 62. S681–S682. 5 indexed citations
8.
Peiffer, Kai‐Henrik, S. Süsser, Johannes Vermehren, et al.. (2015). Interferon lambda 4 genotypes and resistance‐associated variants in patients infected with hepatitis C virus genotypes 1 and 3. Hepatology. 63(1). 63–73. 36 indexed citations
9.
Farnik, Harald, Johannes Vermehren, S. Süsser, et al.. (2015). P0766 : Epidemiology of viral resistance in genotype 1 infected patients at approval of IFN-free DAA combination therapy of chronic hepatitis C in Germany. Journal of Hepatology. 62. S616–S617. 1 indexed citations
10.
Maasoumy, Benjamin, Johannes Vermehren, Birgit Bremer, et al.. (2015). P0877 : HCVRNA levels assessed at early stages of sofosbuvir/ribavirin dual therapy identify relapse patients. Journal of Hepatology. 62. S670–S670. 1 indexed citations
11.
Süsser, S., Sieglinde Kofler, Tania M. Welzel, et al.. (2015). P0896 : Long-term follow-up analysis of RAVs in HCV NS3, NS5A, and NS5B in daa therapy failure patients. Journal of Hepatology. 62. S679–S680. 3 indexed citations
12.
Süsser, S., Eva Herrmann, Christian M. Lange, et al.. (2014). Predictive Value of Interferon-Lambda Gene Polymorphisms for Treatment Response in Chronic Hepatitis C. PLoS ONE. 9(11). e112592–e112592. 18 indexed citations
13.
Vermehren, Johannes, Alessio Aghemo, Kai‐Henrik Peiffer, et al.. (2013). 506 UNDETECTABLE HCV-RNA IN TELAPREVIR-TREATED PATIENTS: LOW CONCORDANCE BETWEEN TWO HIGHLY SENSITIVE REAL-TIME PCR ASSAYS. Journal of Hepatology. 58. S208–S208. 2 indexed citations
14.
Köberle, Verena, Oliver Waidmann, Bernd Kronenberger, et al.. (2013). Serum microRNA‐122 kinetics in patients with chronic hepatitis C virus infection during antiviral therapy. Journal of Viral Hepatitis. 20(8). 530–535. 33 indexed citations
15.
Fevery, Bart, S. Süsser, Oliver Lenz, et al.. (2013). HCV RNA Quantification with Different Assays: Implications for Protease-Inhibitor-Based Response-Guided Therapy. Antiviral Therapy. 19(6). 559–567. 27 indexed citations
16.
Welker, Martin, S. Süsser, Christoph Welsch, et al.. (2012). Modulation of replication efficacy of the hepatitis C virus replicon Con1 by site‐directed mutagenesis of an NS4B aminoterminal basic leucine zipper. Journal of Viral Hepatitis. 19(11). 775–783. 4 indexed citations
17.
Vermehren, Johannes, S. Süsser, Annemarie Berger, et al.. (2012). Clinical utility of the ARCHITECT HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1 infection. Journal of Clinical Virology. 55(1). 17–22. 32 indexed citations
18.
Fevery, Bart, S. Süsser, Oliver Lenz, et al.. (2012). 59 COMPARISON OF TWO QUANTITATIVE HCV RNA ASSAYS IN SAMPLES FROM PATIENTS TREATED WITH A PROTEASE INHIBITOR-BASED THERAPY: IMPLICATIONS FOR RESPONSE GUIDED THERAPY. Journal of Hepatology. 56. S26–S26. 4 indexed citations
19.
Süsser, S., Christoph Welsch, Johannes Vermehren, et al.. (2012). Ultratiefe Pyrosequenz-Analyse (UDPS) von neu beschriebenen seltenen Resistenzvarianten der Hepatitis C Virus NS3 Protease bei Patienten, die mit Telaprevir oder Boceprevir behandelt wurden. Zeitschrift für Gastroenterologie. 50(8). 4 indexed citations
20.
Süsser, S., Johannes Vermehren, Nicole Forestier, et al.. (2011). Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. Journal of Clinical Virology. 52(4). 321–327. 87 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zunaira Awan Breakdown of academic impact, for papers by J. Albrecht Breakdown of academic impact, for papers by K Ohba Breakdown of academic impact, for papers by Atsushi Ozasa Breakdown of academic impact, for papers by Rosanna Fontana Breakdown of academic impact, for papers by Dessislava I. Dimitrova Breakdown of academic impact, for papers by Arleta Kowala‐Piaskowska Breakdown of academic impact, for papers by Uta Naumann Breakdown of academic impact, for papers by J. H. Hoofnagle Breakdown of academic impact, for papers by Vanessa Haynes–Williams
Rankless by CCL
2026